PARE session explores
in patients with RMDs
As many as 40% of patients with systemic lupus erythematosus (SLE) develop kidney disease, which remains a major cause of morbidity, according to Dr. Antonis Fanouriakis of Attikon University Hospital,Athens, and colleagues.
To address this challenge and update clinicians, patients,and others on the latest issues in lupus nephritis treatment,EULAR and the European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) haveupdated their recommendations for lupus nephritis management.
Dr. Fanouriakis will present the new guidelines in theThursday, 4 June, abstract session “Advances in treating SLEand lupus nephritis.” The recommendations were publishedonline ahead of print in Annals of the Rheumatic Diseases.
The researchers followed the EULAR standardised operating procedures for the publication of treatment recommendations. They used Delphi-based methodology to develop
15 questions for a systematic literature review on which tobase the recommendations.
Key changes from the 2012 recommendations include onesfor treatment targets, use of glucocorticoids and calcineurininhibitors, and management of end-stage kidney disease(ESKD).
The target of therapy is a complete response with proteinuria less than 0.5-0.7 g/24 h and “[near-] normal glomerularfiltration rate by 12 months,” according to an abstract forthe session. This can be extended in patients with baselinenephrotic-range proteinuria, the abstract says.
The recommendations also call for long-term treatmentwith hydroxychloroquine with regular ophthalmologic monitoring.
For patients with active proliferative lupus nephritis, the
The psychological impact that COVID-19 has on patients with rheumatic and musculoskeletal diseases (RMDs) in addition to an analysis of emerging data on RMDs and risk factors for COVID-19 will be the focus of presentations at today’s live-streamed COVID-19 PARE session.
Prof. Pedro M. Machado, an associate professor and consultant
in rheumatology and muscle diseases at University College London
and the National Hospital for Neurology and Neurosurgery, also in
London, will explore potential risk factors that have been identified
in an early analysis of 600 patients with RMDs who have contract-
ed COVID-19 in his presentation, “What do COVID-19 data tell us so
far regarding risk factors?”
Rinie Geenen, PhD, a psychologist at Utrecht (Netherlands) Universi-
ty, will follow that with his presentation, “The psychological impact of
COVID-19 on inflammatory rheumatic diseases and how to deal with
eularcongressnews.comThursday 4 June
An authorised publication of the European League Against Rheumatism
Continued on page 11 Continued on page 3